ArticleFrontiers in endocrinology2026
From metabolic syndrome to survival: a prognostic model for PDAC incorporating insulin resistance markers and pathological variables.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic disorders are increasingly recognized as key players in pancreatic ductal adenocarcinoma, yet their prognostic value after surgery remains unclear. Simple and reliable markers such as the triglyceride-glucose (TyG) index offer a practical way to capture insulin resistance and related metabolic disturbances. Method: We retrospectively enrolled 506 patients who underwent curative resection for PDAC. Based on preoperative clinical and postoperative pathological data, we developed three Cox regression models to predict 1-year and 3-year overall survival: a clinical model, a pathological model, and a combined model that integrated both. We evaluated discrimination, calibration, decision curves, and risk stratification, with particular focus on the TyG index and other metabolic variables. Result: The combined model outperformed the others, achieving a validation C-index of 0.721 and AUCs of 0.821 (1-year). The TyG index consistently emerged as the strongest independent predictor across all models (HR up to 1.50). Subgroup analysis by TNM stage revealed that the prognostic impact of the TyG index, body mass index, and albumin varied substantially with disease stage. Decision curve analysis confirmed the combined model's clinical utility, especially when more aggressive intervention is considered. Conclusion: We developed and validated three prognostic models for resected PDAC based on routine clinical and pathological data. The combined model, which integrates metabolic markers such as the TyG index with traditional pathological features, showed the best discrimination and clinical utility. Our results underscore the important role of metabolic dysregulation in postoperative survival. However, these models should serve as supportive tools to inform clinical decision-making rather than replace comprehensive patient assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.